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Abstract 
Strategies for a particular drug delivery are always of great interest for the 
pharmaceutical industry, and efficient methods of preparing products with controlled 
particle microstructures are fundamental for the development and application of drug 
delivery. Supercritical fluid particle design (SCF PD) processes, as a green and 
effective alternative to traditional methods, have been effectively employed to 
produce particles with designated microstructures. 
Combining with research experiences in our research group, this review aims to 
provide a theoretical framework of SCF PD for particular drug delivery. For any drug 
delivery formulations, macroscopic properties are directly influenced by the particle 
microstructures, ³IQYHUVH´ VWUDWHJLHV are introduced at first to obtain the needed 
particle microstructures for a particular drug delivery in this paper. Then, how to 
produce particles with designated microstructures via SCF PD processes is discussed, 
mainly focus on the screening and selection of operating parameters according to 
thermodynamics and fluid dynamics study. Recent examples of SCF micronization 
and co-precipitation/ encapsulation processes are also summarized with an emphasis 
on how to tailor the particle microstructures by controlling the operating parameters. 
Finally, challenges and issues needed further study are briefly suggested for SCD PD. 
 
Keywords: Supercritical fluids, drug delivery, particle design, microstructures, 
process, operating parameters, thermodynamics, fluid dynamics 
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1. INTRODUCTION 
Strategies for effective drug delivery are always of great interest for the 
pharmaceutical industry [1], especially the delivery of particular drugs with poor 
solubility, tissue damage on extravasation, rapid breakdown of the drug in vivo, 
unfavorable pharmacokinetics, poor biodistribution and lack of selectivity for target 
tissues [2-4]. 
Drug delivery process includes the administration of the therapeutic product, the 
release of the active ingredients by the product, and the subsequent transport of the 
active ingredients across the biological membranes to the site of action [5, 6]. For a 
particular drug delivery, macroscopic properties, such as the administration methods, 
drug release and targeting are determined according to the drug properties and its 
application. These macroscopic properties are directly influenced by the particle 
microstructures, such as morphology, particle size (PS), particle size distribution 
(PSD), crystal form, drug loading (DL) and encapsulation efficiency (EE) [7, 8]. Thus, 
the efficient methods of preparing products with controlled particle microstructures 
are fundamental for the development and application of any drug delivery 
formulations. 
York [9] indicated that an ideal particle formation process for the pharmaceutical 
industry should be clean, environmentally responsible, single-step operation 
producing particles with targeted properties. Supercritical fluid (SCF) processes, as an 
alternative strategy of traditional technologies, provide an attractive platform to 
achieve these aims and show great promise in particle design [10, 11]. As the most 
popular SCF, supercritical CO2 (scCO2) is safe, inexpensive, readily available, and an 
ideal substitute for many hazardous and toxic solvents. By controlling the level of 
pressure (P), temperature (T), or modifier, scCO2 dissolves a broad range of 
compounds, both polar and non-polar. At present, scCO2 process is one of the fastest 
growing technologies being adopted by the pharmaceutical industry [12]. 
As noted by Elvassore and Kikic [13@WKHFRQFHSWVRI³FOHDQRUJUHHQFKHPLVWU\´
DQG ³VXVWDLQDEOH WHFKQRORJ\´ DUH RI JUHDW KHOS WR PDNH SKDUPDFHXWLFDO LQGXVWULDO
applications of SCF processes closer than ever. SCF processes and their fundamentals 
have been discussed in many reviews, these reviews mainly focus in the use of SCF 
processes for different pharmaceuticals applications, and occasionally for modeling or 
fundamentals of these processes [14-16]. Combining with research experiences in our 
laboratory, this review aims to provide a theoretical framework of SCF particle design 
(SCF PD) for particular drug delivery. 
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An overall view of SCF PD for particular drug delivery is shown in Fig.1. 
³IQYHUVH´ VWUDWHJLHV are introduced at first to establish the relationship between 
particular drug delivery and particle microstructures. Then, tailoring particle 
microstructures via a suitable SCF processes is discussed with an emphasis on the 
screening and selection of operating parameters according to thermodynamics and 
fluid dynamics study. Typical examples of SCF micronization and 
co-precipitation/encapsulation processes for particular drug delivery are summarized. 
 
2. BASIC REQUIREMENTS OF PARTICULAR DRUG DELIVERY 
For all particular drug delivery, the administration methods of the therapeutic 
product should be determined at first, drugs are introduced into the human body by 
various routes [5, 17], where the selection of these administration methods depends on 
the disease, the effect desired and the product available [18]. The most common 
administration methods with their advantages and disadvantages are listed in Table 1. 
Every administration method has certain requirements on particle microstructures, 
especially on PS [19-23]. Generally, for oral administration, there is a wide PS range, 
which tends to be within 0.1-100Pm, according to their gastrointestinal dissolution 
and absorption characteristics. For injection, the particles in the intravenous solution 
are distributed to various organs depending on PS. Particles larger than 7 Pm are 
trapped in the lungs, and those smaller than 0.1 Pm accumulate in the bone marrow. 
Those with diameter between 0.1 and 7 Pm are taken up by the liver and the spleen. 
For transdermal administration, particles greater than 10 Pm remain on the skin 
surface; particles between 3-10 Pm concentrate in the hair follicles; particles smaller 
than 3 Pm may penetrate both the follicles and stratum corneum. PS also exerts a 
significant influence on pulmonary drug delivery. Particles with mass median 
aerodynamic diameter ranging from 1-5 Pm, are deposited in the bronchial and 
alveolar regions predominantly by sedimentation, and have the best pulmonary 
penetration.  
For most particular drug delivery, the drug release behaviors should also be 
considered. Although vesicles or drug macromolecule conjugates may prolong release, 
optimal control is afforded if the drug is placed in a polymeric material [24]. 
Polymeric materials generally release drugs by the following mechanisms [25]: (i) 
diffusion, (ii) chemical reaction, or (iii) solvent activation. There are two types of 
diffusion-controlled systems: reservoirs (Fig. 2 A) and matrices (Fig. 2 B). Chemical 
control is accomplished either by polymer degradation (Fig. 2 C) or chemical 
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cleavage of the drug from a polymer (Fig. 2 D). Solvent activation involves either 
swelling of the polymer (Fig. 2 E) or osmotic effects (Fig. 2 F and G).  
These drug release mechanisms depend on a number of parameters [26]. Some of 
them are external, such as concentration of the active substance and carrier in the 
surrounding medium, pH, and enzymatic action. However, most of them are particle 
microstructures, such as PS, morphology, crystal form, DL, etc. The quantitative 
interpretation of the values, which obtained in the dissolution assay, is facilitated by 
the usage of a generic equation, where the equation mathematically translates the 
dissolution curve in function of some parameters related with the particle 
microstructures. There are number of kinetic models, which described the overall 
release of drug from the dosage forms [27]. These methods are classified into three 
categories: (a) statistical methods, e.g. exploratory data analysis method, repeated 
measures design, multivariate approach and multivariate analysis of variance [28, 29]; 
(b) model dependent methods, e.g. zero order, first order, Higuchi, Korsmeyer-Peppas 
model, Hixson Crowell, Baker-Lonsdale model and Weibull model [30, 31]; and (c) 
model independent methods [32, 33]. 
Conventional forms of drugs normally medicate the whole body, reaching 
healthy areas as well as diseased. Thus, for some particular drug delivery, the 
transport of the active ingredients to the site of action should be taken into account. 
Targeted drug delivery refers to predominant drug accumulation within a target zone, 
which is independent of the method and route of drug administration [34]. The 
following advantages of drug targeting are evident [35-37]: (a) drug administration 
protocols may be simplified; (b) drug quantity required to achieve a therapeutic effect 
may be greatly reduced as well as the cost of therapy; (c) drug concentration in the 
required sites can be sharply increased without negative effects on non-target 
compartments. There are a number of parameters that are important for the successful 
development and manufacturing of targeted drug delivery. The targeting of drugs may 
be viewed on two levels: (a) organ targeting and (b) cellular targeting. The organ 
targeting is actually dependent on the size, shape and material properties of the carrier 
employed, whereas the cellular targeting depends upon a more specific interaction at a 
molecular level between the carrier and the cellular target. Thus, the targeted delivery 
systems have significant requirements on particle microstructures. For example, 
surface properties of nontargeted drug delivery vehicles affect the particle uptake, 
where the size of the nanoparticles affects their movement in and out of the 
vasculature, whereas the margination of particles to vessel wall is impacted by their 
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shape, as shown in Fig. 3 [38]. 
 
3. SUPERCRITICAL FLUID PARTICLE DESIGN 
Generally, SCF PD processes are classified into three major methods [39], i.e., 
rapid expansion of supercritical solution (RESS), particles from gas-saturated solution 
(PGSS) process, supercritical antisolvent (SAS) process. Table 2 lists their various 
modifications, which depends on whether the scCO2 used as a solvent, a solute or an 
antisolvent. As well known, knowledge about these processes is of great help to the 
selection of a suitable SCF process for a particular drug delivery. 
 
3.1 SCF PD Processes and Their Modifications 
RESS was patented in 1986 [40], and exploits the ability of the scCO2 to 
solubilize different compounds. The advantages of RESS include that it is a simple 
process, and is relatively easy to implement on a small scale. However, the main 
drawback that limits the scaling of this process is represented by great SCF/solution 
rate requirement, since the poor solubility of most pharmaceutical products in scCO2. 
Usually, the solubility value for obtaining a reasonable yield should be on the order of 
10-4 mole fraction. Therefore, several modifications have been implemented for the 
RESS process, including RESS into a liquid solvent (RESOLV) [41], RESS into an 
aqueous solution (RESSAS) [42], RESS-non-solvent (RESS-N) process [43], RESS 
with solid cosolvent (RESS-SC) [44-46], pre-filtration RESS (PF-RESS) [47], etc. 
Recently, these RESS processes were specified by Türk [48]. 
PGSS process uses the property of CO2 can be solubilised in large quantities in a 
liquid or a melted solid [49]. The advantages of the PGSS process are similar to those 
of RESS. These processes perform the production of solvent-free material, as there is 
no need of organic solvents. Further advantages of the PGSS process are low 
consumption of CO2 and a wide range of potential applications, since the solubility of 
compressed gases in liquids and solids is often high. Particularly, PGSS process is 
potentially adaptable to protein and lipid processing, and is properly applied to 
materials with low melting points. Nevertheless, the different physicochemical 
properties of proteins and lipids may result in large and inhomogeneous particles. 
Thus, Salmaso et al [50] developed a novel supercritical gas-assisted melting 
atomization process (GAMA process) to produce the solid lipid submicron particles. 
GAMA process improved the atomization of PGSS process by using a second gas in 
the atomization and precipitation vessel. The PGSS process can also be used to 
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produce particles from aqueous solutions. PGSS-drying is the most used PGSS 
variation, which was developed by Meterc et al [51] for drying of aqueous green tea 
extracts. Compared with spray-drying, PGSS-drying provides an inert atmosphere 
avoiding the possibility of the oxidation. Moreover, PGSS-drying allows drying the 
solutions with a reduced thermal degradation or contamination of the product, because 
PGSS-drying is carried out in a closed system, and only the static mixer section of the 
process operates at high T.  
SAS is devised to precipitate solid compounds that are not soluble in SCF. Many 
variations of the SAS technique exist, including the gas antisolvent (GAS) 
recrystallization, aerosol solvent extraction systems (ASES) and precipitation with 
compressed antisolvent (PCA) process. GAS is a batch process and the earliest SAS 
technology, which was proposed in 1989 by Gallagher et al [52]. ASES and PCA are 
semi-continuous processes, which are devised based on the concept of the GAS. GAS 
process is simple and particularly useful for the crystallization of sensitive materials, 
e.g. pharmaceuticals, biological products, explosives, etc, since it operates at 
moderate T [53]. However, a clear disadvantage of GAS process is the lack of 
effective control on the particle formation. Problems also exist in GAS process, such 
as exothermic impact during the addition of SCF into solvent or solution. Main 
advantage of PCA and ASES over GAS is their suitability for continuous operation, 
which is prerequisite for large scale mass production of particles. To some degree, 
SAS processes usually means ASES or PCA in many researches. In PCA and ASES, 
to minimize particle agglomeration frequently observed and to reduce or eliminate 
drying times, increased mass-transfer rates are required. This has been successfully 
achieved in the solution enhanced dispersion by SCF (SEDS) process [54], which 
uses a coaxial nozzle design with a mixing chamber. In addition, to obtain ultrafine 
particles with narrow size distribution, He et al [55, 56] used SEDS with prefilming 
atomization (SEDS-PA) process. The principle involved in SEDS-PA is to drive the 
liquid atomized along a surface as a film within the nozzle, and consequently reaching 
at the atomizing edge. Besides, the SAS with enhanced mass transfer (SAS-EM) 
technique, conceived by Chattopadhyay and Gupta [57], utilizes a deflecting surface 
that vibrates at ultrasonic frequencies to enhance the atomization of the solution. 
 
3.2 Screening and Selection of Operating Parameters 
As mentioned above, RESS can be used with scCO2-soluble molecules, PGSS 
can be used with CO2-dissolved molecules, while SAS can process nonsoluble 
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molecules. For a particular drug delivery, a suitable method is selected based on the 
drug properties. However, there are many operating parameters for SCF PD processes 
that have great influence on particle microstructures, as shown in Table 2. Study about 
the complicated mechanism of particle formation and growth is essential to screening 
and selection of the operating parameters for producing particles with designated 
microstructures. 
For modeling of SCF processes, a general dynamic equation for simultaneous 
nucleation, condensation and coagulation is implemented, as described in Eq. (1) [58, 
59]. 
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where n denotes the PSD function, t is the time, J is the nucleation rate, v is the 
particle volume, v* is the critical volume, Gis the standard Dirac function, G is the 
condensation growth rate,Eis the Brownian coagulation coefficient. Furthermore, it 
is worthy to notice that the driving force of nucleation and crystal growth for all SCF 
processes is the solution supersaturation (S), which is a measurement of the difference 
of solute concentration between the composition of the fluid (y), and the saturation 
composition (yeq), defined as Eq.(2) [60]. 
eqy
yS                                (2) 
Based on the S value, the particle nucleation and growth kinetics can be established. 
By means of the classical nucleation theory, the nucleation rate J, the critical nucleus 
size r* and the number concentration of critical nuclei N* for homogeneous 
nucleation are given by Eqs. (3-5), respectively [60]. 
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where, Ĭ is the non-isothermal factor, ț is the Zeldovich nonequilibrium factor, Įc is 
the condensation coefficient, ns is the number of condensable molecules, c is the 
mean thermal velocity, ı is the solid-fluid interfacial tension, kB is the Boltzmann's 
constant and vS is the solid molecular volume. After nucleation, the particle assumes 
to grow up until S disappears. The growth of the particles could be governed by the 
diffusion where the diffusion coefficient of the solute in the dense fluid can be 
calculated from the Stokes-Einstein equation. The growth rate of particle diameter 
with t thus may be estimated as given below [61]. 
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where Dp is the diameter of the particles, Kn is the Knudsen number, and DC is the 
diffusion coefficient of the solute in a SCF as follows. 
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P         (7) 
where M is the solvent molecular weight and ȝ is the pure solvent viscosity. 
Thus, S is a key factor to determine the product quality, especially the particle 
microstructures. In general, high S cause fast nucleation and crystal growth, therefore 
a larger number of smaller particles are produced when S is increased. As shown in 
Fig. 4, S is controlled by the thermodynamics and fluid dynamics, which are 
influenced by operating parameters, such as T, P, solvent, nozzle design, flow rate, etc. 
Therefore, to establish the relationship between operating parameters and particle 
microstructures, it is of great importance to get a rational understanding of the 
thermodynamics and fluid dynamics. 
3.2.1 Thermodynamics study 
In a SCF process, thermodynamics is mainly focuses on the study of the 
solubility of the substance in CO2 at high P, maybe with some amount of organic 
solvents. This is vital for setting operating parameters, e.g., T, P and organic solvents. 
Solute solubility data in the SCF can be collected from the literature when they exist, 
or be obtained from experiments or modeling. Solubility data for 783 different 
compounds published from the early 1960s to 2004 are presented by Gupta et al [62]. 
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Solubility data for solid compounds in sub- and supercritical fluids reported in the 
literature between 2005 and 2010 are summarized by S ޣkerget et al [63]. However, 
most of these data are for binary systems, solubility data for ternary and 
multicomponent systems are still limited. Various methods to measure solubility in 
SCF can be divided into two major categories, i.e. static and dynamic [62-64]. For 
example, the supercritical phase behaviors of the poly(lactic acid)/poly(ethylene 
glycol)/poly(lactic acid) (PLLA-PEG-PLLA) + CO2 + dichloromethane (DCM) 
system and the PLLA-PEG-PLLA + CO2 + DCM + Ethanol (EtOH) system were 
investigated using the static method [65]. The effects of T, the mass fraction of DCM 
(or DCM + EtOH) (w), the PEG mass fraction (f) in PLLA-PEG-PLLA on cloud-point 
P were shown in Fig. 5.  
The solubility of a pure solid component in a SCF can be expressed as a function 
of the operating P and T. However, the calculation of phase equilibrium at high P 
presents several peculiarities: (a) many methods originally developed for low P 
calculations, are not applicable at high P; (b) the behavior of the fluid can be strongly 
affected by the presence of a component at near-critical conditions; and (c) the 
mixtures of interest frequently include components with large differences in 
molecular weight or polarity. Models for supercritical-phase equilibriums fall into 
several categories. The most common method treats the SCF phase as a dense gas, 
and uses an equation of state (EOS) to calculate the fugacity coefficient of the solute 
in the fluid phase, e.g., the Peng-Robinson (PR) equation (Eq. (8)) [66, 67]. 
)-()-(-- bvbbvv
a
bv
RTP         (8) 
This type of equations establishes a relation between P, T and molar volume (v). In 
order to take into account the non-ideal behaviour, energetic parameters (a) and 
covolume (b) must be introduced. There are also a large number of semiempirical 
correlations, such as the &KUDVWLO¶V equation (Eq. (9)) [68, 69]. 
)exp(1 BT
Ay c  U         (9) 
Eq. (9) is based on the solvate complex formed between solute and SCF at 
equilibrium, proposing a relation between y and the density of the SCF (ȡ1). It can be 
seen that three parameters (e, A and B) must be determined for Eq. (9) by regressing 
experimental against theoretical data.  
Based on thermodynamic study, phase diagrams can be depicted to decide the 
process paths of various SCF processes. The most applicable phase diagram for the 
binary solid-scCO2 systems in RESS and PGSS is shown in Fig. 6 [70, 71]. The 
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solid-liquid-vapor (S-L-V) lines intersect with the critical lines (L=V) at two 
distinguished point, i.e. the lower critical end point (LCEP) and the upper critical end 
point (UCEP). For RESS, depending on the pre-expansion and expansion of P and T, 
the expansion trajectory may cross the V-L line of CO2, thus leading to the formation 
of liquid CO2 droplets. In some cases, the expansion path may even intersect the S-L 
line of the diagram, so CO2 snow is produced, which causes severe safety problems of 
clogging, especially if CO2 freezes inside the expansion nozzle. In RESS, therefore, it 
is important to predict the behavior of the solubility in the SCF near the UCEP, in 
order to choose P and T values which give the maximum amount of solute in scCO2 
without appearance of a liquid phase. Investigation on the PGSS thermodynamics has 
been performed by Elvassore et al [72] though calculating the enthalpy changes along 
the process with the perturbed-hard-sphere-chain-theory EOS. Results indicated that 
the melting point was found to decrease when increasing P, until a minimum in the 
melting point was reached; afterwards, the melting point was increasing together with 
P. In PGSS, the 3í7 trace of the 6í/í9 equilibrium gives information on P needed 
to melt the solute and form a liquid phase at a given T, and to calculate its 
composition. 
A simple representative phase diagram of the ternary solid-solvent-SCF systems 
at constant T and P is shown in Fig. 7, where dashed arrows represent the process 
paths of various SCF processes. At P above the critical point of the binary organic 
solvent-SCF mixture, the number of coexisting phases reduces from six to four [73]. 
About ternary mixtures, which are mostly related to SAS, a phase behavior study of 
the system is extremely useful to address the feasibility of the process and to exploit 
the effects of T and P [74]. Moreover, alternative polymeric particle topography and 
shapes depended upon process paths followed in the phase diagram were reported. 
For example, Reverchon et al [75] performed an experimental study on SAS 
precipitation to gain insight into the role of phase behavior and atomization in 
controlling morphology and dimension of precipitates. Results showed that operating 
above the mixture critical point (MCP) of the ternary mixture yttrium 
acetate/dimethyl sulfoxide (DMSO)/CO2, sub-micrometric particles were generated 
nearly independently from the size of the injector and of the apparatus. The results 
also show that it is possible to modify the particle dimension by simply changing the 
operating P and/or T in the vicinity of the MCP. The use of a pseudo-binary diagram 
P-molar fraction has been proposed as a base framework to explain the relationship 
between the particle morphology and the phase behavior of processed mixtures. 
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Particularly, it is found that the single-phase region in the gas-rich side of the 
Pícomposition diagram and below the MCP is usefully explored to modify the 
particle dimensions of the precipitate. 
3.2.2 Fluid dynamics 
One of the main aspects of fluid dynamics is the study of jet hydrodynamic, 
which contributes to the nozzle design and selection of other operating parameters. 
Nozzle design includes geometry, size, distance and angle of impact against the 
surface of the jet stream [76]. 
A schematic of the RESS expansion device is displayed in Fig. 8. From the 
nozzle exit, the fluid expands as a supersonic free jet followed by another subsonic jet 
where the jet interacts significantly with the background gas present in the expansion 
region. These two jet regions are separated by the Mach disk [77]. Referring to Fig. 8, 
the relation between the jet height 2r along the expansion pathway to the Mach disk, 
with the distance x is expressed as Eq. 10. 
    
2
2/ nozzle
nozzle
M
Mnozzle DLx
L
DD
r       (10) 
where Lnozzle and LM are the length of the nozzle and the length of the supersonic free 
jet region, respectively, DM denotes the diameter of the Mach disk. The LM and DM 
can be calculated from the following Eqs. (11) and (12) based on the nozzle diameter 
Dnozzle, pre-expansion pressure P0 and expansion pressure Ppost, respectively [78].  
post
0
nozzleM 67.0 P
PDL         (11) 
MM 5625.0 LD           (12) 
Weber et al [79] studied the influence of the capillary geometry by calculating 
the PSD resulting from nozzles with different Lnozzle/Dnozzle ratios. As Lnozzle/Dnozzle 
increases, the major part of the P drop is due to friction and is shifted closer to the exit 
(in normalized distances). Thus, expansions in long capillaries are closer to 
isenthalpic paths, in contrast to the virtually isentropic paths followed by expansions 
in short devices. Size distribution of particles generated in long capillaries is generally 
broader. In expansion devices with high Lnozzle/Dnozzle ratios, bimodal PSD may occur 
because of the second burst of nucleation. Reverchon et al [80] also demonstrates that 
for small Lnozzle/Dnozzle orifices a large part of the P drop, and almost all T decrease 
associated with RESS take place in the post-expansion chamber. This observation 
confirms the important role of the process parameters connected to the post-expansion 
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device. The nozzle needs to be maintained at a suitable pre-expansion T to prevent the 
premature precipitation of the solute. Some researches use the nozzle T as an 
additional parameter for the control of particle characteristics, although the influence 
of this parameter is usually limited [81]. 
PGSS process has similar jet hydrodynamic with RESS process. The nozzle 
hydrodynamics of the PGSS process is contained in the papers of Li et al [82, 83] for 
the CO2 and hydrogenated palm oil (HPO) system. An annular mist flow at the exit of 
the nozzle with an existing equilibrium between the CO2-rich gas phase and the mixed 
CO2-HPO liquid phase was considered. The results indicated that at the exit of the 
nozzle, PSD is narrower with a smaller PS because the particles are formed by melt 
crystallization, but if the particle formation is due to an atomization process, PSD is 
larger and wider. In many cases the number percentage of particles produced by the 
melt crystallization process prevail over that produced by the atomization process. 
Usually, only high pre-expansion T can produce particles mainly from atomization. 
The Dnozzle has only a negligible effect on the produced PS, but has a more evident 
effect on PSD. Large Dnozzle usually produce unimodal distribution particles. 
To study the hydrodynamics of the SAS process, most authors assumed that the 
jet of organic solvent behaves like a liquid jet injected into a gas. This supposition 
allows applying the classic theory of jet break-up. The break-up length of the jet is 
studied and correlated as a function of the Reynolds (Re) and Weber numbers (We), 
defined as Eqs (13) and (14). 
ȝ
uDȡ
Re nozzle=         (13) 
ı
Duȡ
We nozzle
2
=         (14) 
where, u is the velocity.  
However, three different phenomena can be observed when the solution is 
injected into scCO2, i.e., (a) jet break-up into rather large droplets (drops), (b) jet 
atomization into small droplets, and (c) ³JDV-SOXPH´ OLNHPL[LQJ, when no droplets 
are formed, as shown in Fig. 9 [84]. The classic theory of jet break-up is disabled 
when the jet spreads forming a gas-plume.  
To overcome this shortage, Martín et al [85] considered jet hydrodynamics as the 
mixing of two completely miscible fluids forming a gas-plume, and is modeled with a 
k-İ turbulence model, which consists of two semi-empirical equations for the 
turbulent kinetic energy k, and the turbulent kinetic energy dissipation rate İ. 
Lengsfeld et al [86] developed a method for predicting dynamic surface tension and 
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combined this method with linear jet breakup equations to accurately predict jet 
breakup lengths in immiscible to highly miscible systems. For highly miscible 
systems, they proposed that microparticle formation results from gas-phase nucleation 
and growth within the expanding plume, rather than by nucleation within discrete 
liquid droplets.  
Furthermore, Reverchon et al [87] proposed a possible formation mechanism of 
nanoparticles and microparticles, which is based on the competition between two 
characteristic times: (a) time of jet break-up Ĳjb), i.e., the time required to the liquid 
jet to break at the exit of the nozzle; (b)time of surface tension vanishing Ĳstv), i.e., 
the time required to reduce to near zero the surface tension of the liquid in the SCF 
mixture formed in the precipitator. The results indicated that if Ĳstv < Ĳjb, nanoparticles 
IRUPDWLRQ E\ ³JDV WR SDUWLFOH´ SUHFLSLWDWLRQ LV REVHUYHG. Instead, if Ĳstv < Ĳjb, 
microparticles formation by micrometric droplets drying is the prevailing process. 
Further explanations of the occurrence of typically produced particle morphologies 
have been suggested in other works of Reverchon et al [84, 88-90], where the elastic 
or inelastic in situ light scattering techniques were used to gain direct information 
about the mechanisms involved in the SAS process. 
The formation mechanisms of amorphous nano-, micro-, or expanded micro 
particles are well analyzed and well understood based on time scale approaches. 
While, Rossmann et al [91] indicated that this time scale model is not applicable for 
systems forming crystalline structures. The saturation solubility of the solute in 
mixtures of solvents and antisolvents was proposed as the indirect classification 
criterion to distinguish amorphous precipitating or crystallizing. Furthermore, Dowy 
et al [92] developed an optical method to measure the supersaturation in situ for SAS 
process. Firstly, saturation mole fractions of the solute were measured via elastic light 
scattering. Secondly, the actual solute mole fraction was imaged in situ during the 
injection of the solution into the antisolvent using a Raman based optical 
measurement technique.  
Another aspect of fluid dynamics is the study of mass transfer, especially in SAS 
processes. Once the droplets have been formed inside the SCF, rapid transfer of CO2 
into these droplets and the solvent out of these droplets causes the droplets to expand 
rapidly. Werling et al [93] indicated that it is useful to define a droplet radius based on 
the difference in density between the solvent-rich and the antisolvent-rich regions, 
because the droplet radius is a key parameter for describing the extent of mass transfer 
and for determining the effect of process conditions on diffusion. The present mass 
 15 
transfer model is related to droplet turbulence studies, and a simplified continuity 
equation for a chemical species is expressed as Eq. (15) [85]. 
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where Z is the mass fraction, r is the radial direction, z is the axial coordinate. And jr 
is the diffusive flux calculated by simplifying the Maxwell-Stefan equations to the 
well-known Fick law for binary mixtures, which calculated by Eq. (16). 
r
Djr w
w ZU T         (16) 
where DT is the turbulent diffusivity.  
Besides, it is worth to note that in the SAS-EM technique, major factors 
responsible for size reduction are the droplet size reduction due to ultrasonic 
atomization and the increased mixing due to ultrasonic streaming [94]. The droplet 
diameter (D) is proportional to the wavelength on the liquid film surface and can be 
determined as [95]. 
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where F is the vibration frequency. 
 
4. SCF PD PROCESSES FOR PARTICULAR DRUG DELIVERY 
Recently, numerous studies of SCF PD processes have been reported to enhance 
the solubility of poorly water-soluble drugs, design the sustained release systems, and 
develop the targeted systems. The typical SCF PD processes for a particular drug 
delivery are micronization and co-precipitation/encapsulation, as shown in Fig.10.  
Micronization processes tailor PS, PSD and morphology of particles to meet the 
different drug administration methods, improve the bioavailability of pharmaceuticals 
presented in a solid formulation. Furthermore, micronization processes modify the 
physical structure of the crystal to obtain the polymorphic or amorphous forms, which 
might exhibit higher solubility and bioavailability.  
Co-precipitation/encapsulation processes produce drug delivery systems (DDS) 
with anticipated particle microstructures, which effectively improve pharmacological 
and therapeutic properties of a particular drug by controlling the rate, time and place 
of release of drugs in the body.  
 
4.1 SCF Micronization Processes 
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Micronization processes have been gaining increasing importance in particle 
design to produce particles with suitable microstructures, since PS, PSD, morphology 
and sometimes even the crystal form of particles produced in different industries are 
usually not appropriate for the subsequent use. Conventional methods, such as jet and 
ball milling, spray drying and recrystallization using solvent evaporation or liquid 
anti-solvent, have the common disadvantage of poor control of PSD. The 
conventional techniques also face some problems, e.g., thermal and chemical 
degradation of products, large amounts of solvent use and residues. Different with the 
conventional techniques, SCF PD offers a simpler and better control process for the 
development and production of nano- or micro- particle drugs, which easy adapt to 
the principles of green chemistry and green engineering, as well as the new regulatory 
system of process analytical technology and quality by design.  
4.1.1 Objectives of SCF micronization processes 
SCF PD processes have been largely reported to micronize drugs for different 
delivery purposes, which mainly include the following three objectives. 
First, different PS can be produced by one kind of SCF PD processes for a 
particular drug, which means SCF micronization processes meet the requirements of 
different drug administration methods, especially the pulmonary drug delivery. For 
example, Steckel et al [96] micronized 8 different steroids by ASES processes for 
pulmonary delivery, the results showed that the median PS of the steroid particles was 
LQPRVWFDVHVORZHUWKDQȝm and consequently within the respirable range. Todo et 
al [97] improve insulin absorption from dry powder after administration in lung, 
where the dry powders were prepared with or without an absorption enhancer (citric 
acid) by SAS process. Bakhbakhi et al [98] micronized beclomethasone-17, 
21-dipropionate using GAS process, the results showed that the GAS process has the 
potential to produce steroid with powder properties suitable for inhalation therapy.  
Second, SCF micronization processes effectively decrease PS or produce 
amorphous particles, which enhance the dissolution rate and solubility of poorly 
water-soluble drugs. For example, Keshavarz et al [99] micronized raloxifene by 
RESS process, the results showed that raloxifene PS reduced from ȝP to 18.93 
nm, and a 7-fold increase in dissolution rate was obtained. Varshosaz et al [100] 
produced amorphous cefuroxime axetil (CFA) nanoparticles with Z-average PS 
between 158 and 513 nm by RESS process, the results indicated that more than 90% 
of the nano-sized CFA formulations were dissolved in 3 min and complete dissolution 
occurred within 20 min, while the commercial CFA did not achieve complete 
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dissolution during 60 min of the testing period. Kim et al [101] prepared amorphous 
atorvastatin calcium nanoparticles with mean PS ranging between 152 and 863 nm 
using SAS process, the results proved that the dissolution rates were highly increased 
by the reduction of PS resulting in an increased specific surface area, and the 
absorption after oral administration to rats was markedly increased. 
Third, SCF micronization processes also modify the crystal form of the 
polymorphic drugs, which might exhibit higher solubility and bioavailability. Bolten 
et al [102] modified the crystal structure of carbamazepine particles by varying the 
pre-expansion conditions of RESS, the results demonstrated that C-monoclinic 
carbamazepine particles were produced at pre-expansion T higher than 363 K, while 
triclinic carbamazepine particles were produced at 333 K and 300 bar. Rossmann [103] 
crystallized paracetamol particles using SAS process, where the polymorph of 
paracetamol crystals was adjusted between monoclinic and orthorhombic by varying 
the content of ethanol in the solution. Using ethanol as the organic solvent, always the 
monoclinic polymorphic form I of paracetamol was generated irrespectively of the P 
and the concentration. It was also found that already 30% of acetone in the initial 
mixture is sufficient to change the polymorphic form from monoclinic to 
orthorhombic. Recrystallzation and micronization of 10-hydroxycamptothecin (HCPT) 
was investigated using SAS process in our previous study [104], as shown in Fig.11, 
two different polymorphs were found, the results also indicated that SAS process 
modified the form of HCPT from monohydrate to anhydrous. 
4.1.2 Tailoring particle microstructures via SCF micronization processes 
The main objective of SCF micronization processes is to produce micro- and/or 
nanoparticles with controlled PS, PSD, morphology and crystal form. Some recent 
reports of SCF micronization processes are exampled in Table 3, which focus on how 
to tailor the PS by manipulating the operating parameters.  
Thermodynamics are considered at first in many studies to guide the formation 
of drug fine particles. Huang et al [105] determined the solubility of progesterone and 
correlated the solubility data with three empirical density-based models and the PR 
EOS model before preparing progesterone fine particles with RESS. Solubility of 
solute in the scCO2, which is mainly controlled by extraction T and P, is an important 
factor for the particle formation in the RESS process, because it is directly related to S. 
The results showed that increased with increasing extraction P. Besides, high 
extraction T induces low progesterone concentration as constant extraction P is lower 
than the crossover P of 210 bar, but induces high progesterone concentration as 
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extraction P is higher than 210 bar. And small progesterone particles were obtained at 
high extraction P or T. Based on the progesterone solubility data, effect of extraction 
T and P on the average PS of produced materials are predicted and explained 
combined with the crystal nucleation rate and growth by coagulation or by 
condensation after nuclei. 
Chen et al [109] employed a modified PGSS process to prepare 
PEG6000-ibuprofen composite particles after investigating the S-L-V phase 
equilibrium behavior of the PEG6000-ibuprofen-CO2 system. Then the composite 
powder was then dispersed into water to remove PEG6000 and obtain ibuprofen 
nanoparticles. The results showed that increase of the P decreases the melting T of the 
ibuprofen-PEG6000 mixture. According to the thermodynamics data, suitable 
operating T and P at different PEG molecular weight were selected, and spherical 
ibuprofen nanoparticles with diameter of 20-500 nm were prepared at different 
conditions.  
Theophylline microparticles were prepared by Franceschi et al [114] using SAS 
process, where a mixture of EtOH and DCM was used as solvents. In order to help 
selecting the appropriate operating conditions and understand the precipitation 
mechanism, the fluid phase behavior of ternary (CO2-solvents) and quaternary 
(CO2-solvents-theophylline) systems were investigated using a static synthetic method. 
Phase diagram of the mixture revealed that the contact mechanism between solution 
and antisolvent occurred in two different ways, which influenced the aggregation, PS 
and PSD. The results verified that the addition of theophylline to the ternary system 
consisting of the organic solvents and CO2 did not influence the transition P, which 
allows the consideration of a ternary system to select the operating points in the phase 
diagram. PR-EOS demonstrated to be suitable for representing multicomponent 
systems. The precipitation T, flow rate of solution (Fs) and scCO2 (Fc), and Cd in the 
solution were the most important variables that affected the precipitation results. 
 Ultra-fine particles of Į-chymotrypsin were produced with SAS technique by 
Chang et al [115], it was found that the phase behavior of the mixtures during 
precipitation governed the product's morphology, as shown in Fig. 12. Uniform 
networked nano-particles were obtained as the precipitation was implemented in the 
supercritical region. The uniformity of the resulting products became worse when 
the particles were precipitated around the critical region. Irregular micro-scale 
aggregated particles were formed in the superheated region, while both dense cake 
and spherical clusters were produced in the V-L coexistence region. 
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Fluid dynamics is essential to discuss the influence of flow rate and nozzle 
design on particle microstructures. Micronization of gemfibrozil particles was carried 
out using RESS process by Baseri et al [116], where effects of spray distance, nozzle 
type and nozzle diameter on the characteristics of gemfibrozil particles were studied. 
The results showed that two competition phenomena for spray distance, i.e., 
increasing effect (increase of growth time by increasing of spray distance) and 
decreasing effect (decrease of flow velocity by increase of spray distance) lead to 
make a maximum value of mean PS in the spray distance of 5.5 cm.  Particles 
produced by capillary nozzle have higher growth time and it results in larger particles 
in comparison with the orifice nozzle. A larger diameter of nozzle provides only 
higher total flow rates without bringing about a change of axial velocity, thus it has 
insignificant effect on the crystallization process.  
He et al [55] precipitate ephedrine from ethanol solution using SEDS-PA process, 
where a prefilming atomizer was designed on the basis of the mechanisms of 
atomization and applied to the SEDS process. It was found that PS decreases with 
increasing Fc, because high Fc reinforced the impingement of dense gas on the liquid 
film, which results in the formation of fine droplets and intense mixing of scCO2 and 
droplets. With the increase of Fs, PS increased in the beginning, then decreased. When 
Fs is low and Fc is relatively high, the impingement of the atomizing dense gas on 
liquid sheet is the main factor of jet breakup in the spray process and the liquid sheet 
is rapidly disintegrated into droplets as prompt atomization; drop sizes and PS 
increase with Fs for constant Fc in this case. When Fs is high and Fc is relatively low, 
the interaction between the liquid and the dense gas is weak and the liquid sheet is 
disintegrated into drops according to the wavy-sheet mechanism; in this case, PS 
decrease with Fs for constant Fc.  
Micronization of camptothecin (CPT) has been performed using SAS process in 
our previous study [117]. The results indicated that solvents with higher ȡ/ȝ ratio, 
lower ı and lower solvation power will form smaller CPT microparticles with lower 
crystallinity. The possible reason is that higher ȡ/ȝ means the higher Re of solution at 
the nozzle exit, and low ı of the pure liquid shortens the elapsed time of the interface 
between injected solution and bulk CO2. These are beneficial to the formation of 
VPDOOGURSOHWVRU³JDV-SOXPH´, which provide a larger mass transfer surface between 
the liquid and the gaseous phase, resulting in a faster S of the solute occurring and less 
time for the particle growth, then forming small particles. On the other hand, at same 
CPT concentration, the saturation ratio is higher when using solvents with lower 
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solvation power, and this helps to produce smaller particles. 
 
4.2 SCF Co-precipitation/Encapsulation Processes 
The formulation of drugs together with a biocompatible or biodegradable carrier 
material by co-precipitation/encapsulation processes has a great relevance for 
pharmaceutical industry. Usually, co-precipitation/encapsulation techniques are 
divided into three classes: (a) chemical processes like molecular inclusion or 
interfacial polymerization; (b) physicochemical techniques like coacervation and 
liposome encapsulation; (c) physical processes like spray drying, co-crystallization, 
extrusion or fluidized bed coating. However, major advances in drug manufacture 
have highlighted the limitations of conventional particle formation and pretreatment 
processes in fine-tuning the characteristics required, since the harsh processing 
conditions and poor properties of products. The application of SCF PD as an 
alternative to the conventional processes has been an active field of research and 
innovation during the past two decades.  
4.2.1 Objectives of SCF co-precipitation/encapsulation processes 
First, sustained release systems can be designed by SCF co-precipitation/ 
encapsulation processes. For example, Duarte et al [118] prepared Ethylcellulose/ 
methylcellulose blends by solvent-evaporation and SAS process. Then, SCF 
impregnation was performed to prepare naproxen loaded microspheres. The results 
indicated that microspheres prepared by SAS process have a higher loading capacity 
and present a slower release profile. The systems studied present a release mechanism 
controlled by drug diffusion, which complies Fick's law of diffusion.  
Lee et al [119] employed a modified SAS-EM process to fabricate 
controlled-release matrices for Paclitaxel. When ultrasonication was applied, more 
uniform particles in the submicron size range were obtained. In vitro release studies 
showed that, at DL of 3% or less, almost the entire drug is released during a 1 month 
period. At higher DL (10%), approximately half the drug is released during a 1 month 
period and subsequent release is very slow. A similar result is obtained at 5% DL. This 
is very likely due to the formation of drug crystals dispersed within the polymer 
matrix. Similar phenomenon was observed at our previous work [120], where the 
micronized HCPT is dispersed into the PLLA matrix using SAS process. The result of 
in vitro drug release test indicated that the crystallinity of HCPT in microparticles 
affects the control release performance, and the good encapsulated microparticles with 
higher DL and higher crystallinity are better.  
10-Hydroxycamptothecin proliposomes (HCPT-PL) were also prepared using the 
SAS process in our previous study [121], the results showed that spherical or clavate 
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HCPT-PL were obtained under different DL, as shown in Fig. 13. For the optimized 
HCPT-PL, the residual DCM meets the ICH requirement, and part of the encapsulated 
HCPT still maintains its crystalline state. The result of in vitro release rate study 
showed that HCPT-PL sustained the HCPT release rate successfully, where the drug 
release of the optimized HCPT-PL followed the first order kinetics, and the drug 
diffusion mainly corresponded to a Fickian diffusion mechanism during the first 10 h.  
SCF co-precipitation/encapsulation processes are also employed to produce 
targeted DDS. One way for achieving targeting of specific cell types is suggested that 
modifying the carrier materials with the targeting moieties, such as ligands, peptides 
or aptamers. Among them, folate (FA) is one of the most common targeting moieties, 
and has been covalently attached to a wide array of drug delivery carriers. 
For example, Zu et al [122] prepared FA-dextran-CPT tumor-targeted 
nanoparticles by SAS process. Under the optimum operation conditions, 
FA-dextran-CPT nanoparticles with a mean PS of 182.21 nm were obtained, and the 
EE and LD were 62.13% and 36.12%, respectively. Compared with other methods for 
preparing tumor-targeted nanoparticles, the SAS process is uncomplicated to 
implement. Moreover, Results suggest FA-dextran-CPT nanoparticles have excellent 
potential in drug delivery systems for cancer chemotherapy.  
Zhao et al [123] prepared HCPT-chitosan (HCPT-CS) nanoparticles by the 
SAS-ionic crosslink combination method; the resulting HCPT-CS nanoparticles were 
then conjugated with folate for specific targeting. Optimum conditions for preparing 
desired HCPT-CS nanoparticles with a mean PS of 173.5 nm and entrapment 
efficiency of 77.3% were obtained. The resulting FA-HCPT-CS nanoparticles reveal 
that the amount of folate conjugation was 197.64 mg/g CS. FA-HCPT-CS 
nanoparticles used in drug carrier systems could have potential value in 
HCPT-sensitive tumors. 
Another way for drug targeting is using polymer/magnetite particles, which is 
based on the attractive forces between the applied magnetic field at the target site and 
the magnetic material dispersed within the drug-loaded polymer particles. Vezzù et al 
[124] produced lipid microparticles magnetically active by a modified PGSS process. 
The EE of magnetite nanoparticles was about 30% and increased with the 
concentration of magnetite in the initial mixture. The possibility to drive these 
magnetically active particles by an external magnet was demonstrated in a simple 
apparatus simulating a vessel of the circulatory system. The coating of magnetite 
nanoparticles with lipids by the modified-PGSS process presently developed provides 
materials which may be interesting for diagnostic and therapeutic applications.  
 22 
Chattopadhyay et al [125] used SAS and SAS-EM processes to produce 
magnetite-encapsulated PLGA, PMMA and Eudragit RS biodegradable polymer 
particles via co-precipitation of the polymer with a suspension of magnetite particles 
in mineral oil and a fatty acid surfactant, where DCM is solvent. Chen et al [126] 
prepared Fe3O4-PLLA-PEG-PLLA magnetic microspheres (MMPs) in a process of 
suspension-enhanced dispersion by supercritical CO2, a modified SEDS process by 
HPSOR\LQJ WKH ³LQMHFWRU´-like suspension delivery system. Methotrexate-loaded 
Fe3O4-PLLA-PEG-PLLA MMPs were produced by co-precipitation and 
microencapsulation processes. The resulting MMPs had a spherical shape, with a 
good magnetic response, which would have potential as a sustained and targeted drug 
delivery system when combined with the microencapsulation process.  
4.2.2 Tailoring particle microstructures via SCF co-precipitation/encapsulation 
processes 
Besides PS, PSD, morphology and crystal form, particle microstructures like DL 
and EE are essential to be tailored for SCF co-precipitation/encapsulation processes. 
Table 4 lists recent SCF co-precipitation/encapsulation processes with an emphasis on 
the effects of operating parameters on PS, DL and EE. Although a fairly general 
experimental result of the effects of operating parameters on particle microstructures 
is not available up to now, some correlations have been proposed and rationally 
explained on the basis of the thermodynamics and fluid dynamics knowledge. 
Typical examples for RESS co-precipitation/encapsulation processes are as 
follow. Kim et al [134] investigated the effects of fluid phase interactions on particle 
formation using RESS though combining the solubility data with morphology studies. 
The solubility of PLLA and naproxen/ PLLA was measured by using a dynamic flow 
apparatus, and correlated by the lattice fluid theory of Sanchez and Lacombe. The 
results suggested that the value of having phase equilibrium data corresponding to 
morphology studies was the ability to calculate S and accurately describe where 
precipitation begins to take place in the nozzle. For the co-precipitation of PLLA and 
naproxen, PLLA microspheres (10- ȝP ORDGHG ZLWK QDSUR[HQ DQG VRPH IUHH
naproxen microparticles (1-5 ȝPZHUHREVHUYHGDWDSUH-expansion T of 114 °C and 
an extraction P of 190 bar, and the composite particles consisted of a naproxen core 
surrounded by a thin polymer coating. 
Songtipya et al [127] produce catechin/PLLA nanoparticles using RESOLV. The 
results showed that Cd, pre-expansion T and P had no significant effect on the shape 
and size of composite nanoparticles, which indicated that rapid expansion into a 
receiving solution effectively interrupted the collision and growth of particles in the 
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free jet. While, the DL and EE of catechin increased with increasing pre-expansion T, 
and with decreasing pre-expansion P and Cd. The effect of pre-expansion T and P 
could be explained by the degree of saturation (s) of catechin solutions, increasing 
pre-expansion T and decreasing pre-expansion P resulted in increasing S and hence a 
higher nucleation rate of catechin, as well as increased catechin precipitation and 
entrapment in PLLA along the expansion path. In addition, during rapid expansion, 
catechin tended to precipitate preferentially in the form of its own particles instead of 
being entrapped in PLLA with increasing Cd. However, different results were found by 
Sane et al [128], where asiatic acid/ PLLA nanoparticles were successfully produced 
by RESOLV, the results indicated that the DL and EE increased with increasing Cd/Cc, 
but decreased with increasing pre-expansion T.  
Typical examples for PGSS co-precipitation/encapsulation processes are as 
follow. Rodrigues et al [129] obtained theophylline/HPO microcomposites by PGSS, 
the results showed that P had no significant effect on PS. However, particles shaped 
like needles, threads or fibers were more abundant at low pre-expansion P. 
Conversely, spheres were predominant at higher pre-expansion P. A reasonable 
explanation was proposed that at higher pre-expansion P, higher fluid densities are 
obtained and nucleation starts later in the expansion path. Dissolution studies showed 
that the Brophy and Deasy model was more adequate to follow the long-time drug 
dissolution kinetics for the HPO/theophylline system. However, a significant burst 
effect was observed because considerable amounts of theophylline were located at the 
particles surface. 
de Paz E et al [130] encapsulated ȕ-carotene in soybean lecithin using 
PGSS-drying technique. The influence of process variables on PS was correlated with 
the atomization process, which was enhanced by increasing the amount of CO2 
dissolved in the solution and the volumetric expansion ratio in the nozzle. The results 
also suggested that a basic requirement for a high EE was a good dispersion of the 
material to be encapsulated within the carrier matrix in the static mixer. If the 
pre-expansion T was increased, more water was extracted in the static mixer because 
the solubility of water in CO2 increased with T, thus, the EE increased when the 
pre-expansion T was increased. Besides, with a concentrated solution of lecithin 
already formed in the static mixer, particles or oil droplets can more easily be 
surrounded by a shell of carrier material that can be mantained upon drying in the 
spray tower, leading to the prodution of microcapsules and an increase of the EE. 
Typical examples for SAS co-precipitation/encapsulation processes are as follow. 
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Fraile et al [113] encapsulated quercetin in Pluronic F127 poloxamers by SAS process, 
the results suggested that for low-melting-T polymer, the particles were formed not by 
nucleation from the solution by the anti-solvent effect, but rather by solidification 
from a polymer melt. Although operation near the melting region was 
disadvantageous for the micronization of a pure polymer, it was a favorable condition 
for co-precipitation experiments, because it can facilitate the encapsulation of the 
active compound through the formation of a polymer film over active-component 
particles, avoiding the crystallization of segregated particles of active compound and 
polymer. The results also indicated that viable conditions for SAS co-precipitation of 
quercetin with Pluronic F127 were limited to a narrow range of Cd/Cc, in which 
quercetin particles can act as nucleation sites for the formation of polymer films. 
Further, formulations exhibited faster dissolution and a higher final solubility in 
simulated gastric and intestinal fluids, because of the morphological and structural 
properties conferred by SAS process. 
Montes et al [131] co-precipitated Naproxen with Eudragit or PLLA by SAS 
process. For Naproxen-Eudragit systems, a larger PS was obtained with a lower P. 
This result can be explained by considering that an increase in P at constant T 
enhances the solvent power of scCO2 toward the solvent, meaning that the liquid 
solvent molecules are more strongly captured by the CO2, thus reducing the possible 
interaction between solvent, polymer and drug. The Cd /Cc had a negligible effect on 
PS but the DL was higher when a higher Cd /Cc ratio was used. The in vitro release 
profiles of the Naproxen-Eudragit and Naproxen-PLLA systems showed a slower and 
more controlled release in comparison to the untreated Naproxen. 
Chen et al [132] prepared morphine-loaded PLLA and PLLA-PEG-PLLA 
microparticles by the SEDS process. Results showed that the actual DL increased with 
the increase of theoretical dosage while the EE decreased. The precipitated morphine 
particles might act as host particles, which lead to easy encapsulation of morphine by 
the precipitation of PLLA-PEG-3//$SDUWLFOHV7KH µVRIW¶ VHJPHQW3(*JUDIWHGRQ
the PLLA-PEG-PLLA made a great impact on the precipitation of microparticles, 
since the hydrophilicity of PEG and the increase of PEG content increased the 
solubility of copolymer in organic solvent. The release behaviors of microparticles 
varied greatly with the PEG content in the PLLA-PEG-PLLA copolymer, showing 
short-term release with burst release followed by sustained release within days or 
long-term release lasted for weeks. 
Zabihi et al [133] successfully encapsulated nano-curcumin in poly(lactic-co- 
glycolic acid) through SAS-EM process, where poly(lactic-co-glycolic acid) solution 
was sprayed into scCO2 media, in which nano-curcumin particles were fluidized by 
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ultrasonic vibration. The size and yielding of products decreased with increasing Fs. 
But the DL first decreases and then increases slightly. Ultrasonic power exhibited a 
crucial influence on microcapsules characteristics. Products had higher DL and higher 
yield with increasing ultrasonic power, which was owe to better mixing effects. In the 
other hand, higher ultrasonic power caused higher fluidization potential by which 
nano-curcumin was distributed more uniform in precipitation vessel, and resulted 
more efficient loading. High Fc also improved the DL and PSD when the ultrasonic 
power was high enough to prevent the particles being pulled out by net flow. 
Besides, the effects of the various conditions on PS and PSD in SAS 
encapsulation process have been discussed in detail by Kalani et al [135]. The main 
factors for choosing the solvent and biodegradable polymer to produce fine particles 
to ensure effective drug delivery were emphasized and the effect of polymer structure 
on drug encapsulation was illustrated. 
 
5. SUMMARY AND CHALLENGES 
Major advances in drug delivery over recent years have highlighted the 
requirements of efficient methods for producing particles with designated 
microstructures. SCF processes, as a green and effective alternative to traditional 
method, have many advantages in particle design and show great potential in drug 
micronization and co-precipitation/encapsulation.  
In this review, a theoretical framework of SCF PD is put forward for particular 
drug delivery, where the relationships among SCF processes, particle microstructures 
and performances are discussed in detail. Particle microstructures can be effectively 
tailored by controlling the operating parameters of SCF processes, where knowledge 
about the complicated mechanism of particle formation and growth is expected to 
help the screening and selection of suitable SCF process and its corresponding 
operating parameters. However, challenges and issues are still existed and need 
further study for the commercialization of SCF PD, such as following. 
(a) Many researches have proved that the macroscopic properties of a drug delivery 
formulation are depend on the particle microstructures, however, it is still difficult 
to gain clear and definite requirements of a particular drug delivery on particle 
microstructures. 
(b) Many different SCF processes have been developed and used for particle design, 
but it is difficult to choose a suitable SCF process for a particular drug delivery, 
because of the limited knowledge of complicated mechanism involved in SCF 
processes and insufficient fundamental solubility data of many drugs and/or 
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carrier materials in SCF. 
(c) Although many of the nucleation and crystal growth mechanism and models 
involved in SCF processes have been proposed, it can only qualitatively predict 
the microstructures of the produced particles under different operating parameters, 
it is still difficult to get a quantitative prediction. Rational explanations and 
influence mechanisms of operating parameter on particle microstructures have 
been reported in most experimental studies. But in-depth thermodynamic and 
fluid dynamic study is not enough to determine a precise process path, and to 
screen and select the corresponding operating parameters. 
(d) The industrialization of SCF PD processes have been considered and developed 
in recent years, but valid models or experience based on the experimental data are 
very limited to perform the scale-up of a pilot or industrial scale. 
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ABBREVIATIONS 
a, b   =  parameters of Peng-Robinson equation 
ASES  =  Aerosol solvent extraction systems 
c   = mean thermal velocity 
Cc   = Carrier material concentration 
Cd   = Drug concentration 
CFA  = Cefuroxime axetil 
CS   = Chitosan 
D   = Droplet diameter 
DCM  = Dichloromethane 
DC   = Diffusion coefficient  
DDS  = Drug delivery systems  
DL   = Drug loading 
DM   = Diameter of the Mach disk 
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DMSO  = Dimethyl sulfoxide 
Dp   = Diameter of the particles 
Dnozzle  = Nozzle diameter  
DT   = Turbulent diffusivity 
EOS  = Equation of state 
EtOH  = Ethanol 
e, A and B =  parameters of &KUDVWLO¶V equation 
EE   = Encapsulation efficiency 
F   = Vibration frequency 
f   =  PEG mass fraction in PLLA-PEG-PLLA 
FA   =  Folate 
Fc   = scCO2 flow rate 
Fs   =  Solution flow rate 
G   =  Condensation growth rate 
GAMA  =  Gas-assisted melting atomization 
GAS  = Gas antisolvent 
HCPT  = 10-Hydroxycamptothecin 
PL   = Proliposomes 
HPO  = Hydrogenated palm oil 
IPA   = Isopropyl alcohol 
J   = Nucleation rate 
jr    = diffusive flux 
k   = turbulent kinetic energy 
kB   = Boltzmann's constant 
Kn   = Knudsen number 
LCEP  = Lower critical end point 
LM   = Length of the supersonic free jet region 
Lnozzle  = Length of the nozzle 
M   = Solvent molecular weight 
MCP   = Mixture critical point 
MMPs   = Magnetic microspheres 
n   = Particle size distribution function 
N*   = Critical nuclei number concentration 
P   = Pressure 
P0   = Pre-expansion pressure 
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PCA  = Precipitation with compressed antisolvent 
PEG  = Poly(ethylene glycol) 
PF-RESS = Pre-filtration rapid expansion of supercritical solution 
PLLA  = Poly(lactic acid) 
Ppost  = Expansion pressure  
PR   = Peng-Robinson 
PS   = Particle size 
PSD  = Particle size distribution 
r   = radial direction. 
r*   = critical nucleus size  
Re   = Reynolds 
RESOLV = Rapid expansion of supercritical solution into a liquid solvent 
RESS  = Rapid expansion of supercritical solution 
RESS-N = Rapid expansion of supercritical solution with a non-solvent 
RESS-SC = Rapid expansion of supercritical solution with solid cosolvent 
S   = Supersaturation 
s   = degree of saturation 
S-L-V  = Solid-Liquid-Vapor 
SAS  =  Supercritical antisolvent 
SAS-EM  = Supercritical antisolvent with enhanced mass transfer 
ScCO2   = Supercritical CO2 
SCF  =  Supercritical fluids 
SCF PD  = Supercritical fluid particle design 
SEDS  =  Solution enhanced dispersion by supercritical fluids 
SEDS-PA =  SEDS with prefilming atomization 
T   = Temperature 
t   = time 
u   = velocity 
UCEP  = Upper critical end point 
v   = volume 
v*   = critical volume 
vS   = solid molecular volume 
w   = mass fraction of DCM (or DCM + EtOH) 
y   = solute concentration 
yeq   = saturation solute concentration 
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z   = axial coordinate 
Įc   = condensation coefficient
E     Brownian coagulation coefficient 
G   = standard Dirac function 
İ   = dissipation rate 
ț   = Zeldovich nonequilibrium factor 
ȝ   = viscosity 
Ĭ   = non-isothermal factor 
ȡ1   = density of supercritical fluids 
ı   = interfacial tension 
Ĳjb   = time of jet break-up  
Ĳstv   = time of surface tension vanishing 
Z     mass fraction 
 
REFERENCES 
[1] Allen TM, Cullis PR. Drug delivery systems: entering the mainstream. Science 2004; 303: 
1818-1822.  
[2] Fahr A, Liu X. Drug delivery strategies for poorly water-soluble drugs. Expert Opin Inv Drug 
2007; 4: 403-416.  
[3] Loira-Pastoriza C, Todoroff J, Vanbever R. Delivery strategies for sustained drug release in 
the lungs. Adv Drug Deliver Rev 2014; 75: 81-91. 
[4] Sun Y. Supercritical Fluid Particle Design for Poorly Water-soluble Drugs (Review). Curr 
Pharm Design 2014; 20:349-368. 
[5] Jain KK. Drug delivery systems-an overview. In Jain KK (Ed), Drug Delivery Systems, 
Humana Press 2008: pp. 1-50. 
[6] Rishikesh, Faruki MZ, Ghosh DR. Tailored Release Drug Delivery System (TRDDS), Int Res 
J Pharm App Sci 2012; 2: 128-137. 
[7] Jain A, Bollinger JA, Truskett TM. Inverse methods for material design. AIChE J 2014; 
00:1-9 
[8] Aguilera JM. Why food microstructure?. J Food Eng 2005; 67: 3-11. 
[9] York P. Strategies for particle design using supercritical fluid technologies. Pharm Sci Tech 
today 1999; 2: 430-440. 
[10] Cansell F, Aymonier C. Design of functional nanostructured materials using supercritical 
fluids. J Supercrit Fluid 2009; 47: 508-516. 
[11] Ginty PJ, Whitaker MJ, Shakesheff KM, et al. Drug delivery goes supercritical. Mater today 
2005; 8: 42-48.  
[12] Fages J, Lochard H, Letourneau JJ, et al. Particle generation for pharmaceutical applications 
using supercritical fluid technology. Powder Technol 2004; 141: 219-226.  
[13] Elvassore N, Kikic I. Pharmaceutical processing with supercritical fluids. In: Bertucco A, 
Vetter G, Eds. High Pressure Process Technology: Fundamentals and Applications. 
Netherlands: Elsevier 2001; pp. 612-625 
 30 
[14] Martín Á, Varona S, Navarrete A, et al. Encapsulation and co-precipitation processes with 
supercritical fluids: applications with essential oils. Open Chem Eng J 2010; 4: 31-41. 
[15] Sekhon BS. Supercritical fluid technology: an overview of pharmaceutical applications. Int J 
Pharm Tech Res 2010; 2: 810-826. 
[16] Tabernero A, Martín del Valle EM, Galán MA. Supercritical fluids for pharmaceutical 
particle engineering: Methods, basic fundamentals and modelling. Chem Eng Process 2012; 
60: 9-25. 
[17] Üner M, Yener G. Importance of solid lipid nanoparticles (SLN) in various administration 
routes and future perspectives. Int J Nanomed 2007; 2: 289. 
[18] Rowland M. Influence of route of administration on drug availability. J Pharm Sci 1972; 61: 
70-74. 
[19] Shekunov BY, Chattopadhyay P, Tong HHY, Chow AHL. Particle size analysis in 
pharmaceutics: principles, methods and applications. Pharm Res 2007; 24: 203-227.  
[20] Gaumet M, Vargas A, Gurny R, et al. Nanoparticles for drug delivery: the need for precision 
in reporting particle size parameters. Eur J Pharm Biopharm 2008; 69: 1-9. 
[21] Desai MP, Labhasetwar V, Amidon GL, et al. Gastrointestinal uptake of biodegradable 
microparticles: effect of particle size. Pharm Res 1996; 13: 1838-1845. 
[22] Kohli AK, Alpar HO. Potential use of nanoparticles for transcutaneous vaccine delivery: 
effect of particle size and charge. Int J Pharm 2004; 275: 13-17. 
[23] Pilcer G, Amighi K. Formulation strategy and use of excipients in pulmonary drug delivery. 
Int J Pharm 2010; 392: 1-19. 
[24] Fu Y, Kao WJ. Drug release kinetics and transport mechanisms of non-degradable and 
degradable polymeric delivery systems. Expert Opin Drug Del 2010; 7: 429-444. 
[25] Langer R. New methods of drug delivery. Science 1990; 249: 1527-1533.  
[26] Korsmeyer RW, Gurny R, Doelker EM, Buri P, Peppas NA. Mechanism of solute release 
from porous hydrophilic polymers. Int J Pharm1983; 15: 25-35. 
[27] Dash S, Murthy PN, Nath L, et al. Kinetic modeling on drug release from controlled drug 
delivery systems. Acta Pol Pharm 2010; 67: 217-223. 
[28] Mauger JW, Chilko D, Howard S. On the analysis of dissolution data. Drug Dev Ind 
Pharm1986; 12: 969-992. 
[29] Polli JE, Rekhi GS, Augsburger LL, et al. Methods to compare dissolution profiles and a 
rationale for wide dissolution specifications for metoprolol tartrate tablets. J Pharm Sci 1997; 
86: 690-700. 
[30] Costa P, Lobo JMS. Modeling and comparison of dissolution profiles. Eur J Pharm Sci 2001; 
13: 123-133. 
[31] Papadopoulou V, Kosmidis K, Vlachou M, et al. On the use of the Weibull function for the 
discernment of drug release mechanisms. Int J Pharm 2006; 309: 44-50. 
[32] Costa P. An alternative method to the evaluation of similarity factor in dissolution testing. Int 
J Pharm 2001; 220: 77-83. 
[33] Shah VP, Tsong Y, Sathe P, et al. In vitro dissolution profile comparison-statistics and 
analysis of the similarity factor, f2. Pharm Res 1998; 15: 889-896. 
[34] Bae YH, Park K. Targeted drug delivery to tumors: myths, reality and possibility. J Control 
Release 2011; 153: 198-205. 
[35] Torchilin VP. Drug targeting. Europ Eur J Pharm Sci 2000; 11: S81-S91. 
 31 
[36] Ruenraroengsak P, Cook JM, Florence AT. Nanosystem drug targeting: facing up to complex 
realities. J Control Release 2010; 141: 265-276. 
[37] Florence AT, Halbert GW. Drug delivery and targeting. Phys Tech 1985; 16: 164-170. 
[38] Farokhzad OC, Langer R. Impact of nanotechnology on drug delivery. ACS nano 2009; 3: 
16-20. 
[39] Perrut M, Clavier JY. Supercritical fluid formulation: process choice and scale-up. Ind Eng 
Chem Res 2003; 42: 6375-6383. 
[40] Smith RD, inventor. Supercritical fluid molecular spray film deposition and powder 
formation. US Patent 4582731. 1986. 
[41] Sane A, Limtrakul J. Formation of retinyl palmitate-loaded poly (l-lactide) nanoparticles 
using rapid expansion of supercritical solutions into liquid solvents (RESOLV). J Supercrit 
Fluid 2009; 51: 230-237. 
[42] Young TJ, Mawson S, Johnston KP, et al. Rapid Expansion from Supercritical to Aqueous 
Solution to Produce Submicron Suspensions of Water-Insoluble Drugs. Biotechnol Progr 
2000; 16: 402-407. 
[43] Mishima K, Matsuyama K, Tanabe D, et al. Microencapsulation of proteins by rapid 
expansion of supercritical solution with a nonsolvent. AIChE J 2000; 46: 857-865. 
[44] Thakur R, Gupta RB. Formation of phenytoin nanoparticles using rapid expansion of 
supercritical solution with solid cosolvent (RESS-SC) process. Int J Pharm 2006; 308: 
190-199. 
[45] Thakur R, Gupta RB. Rapid expansion of supercritical solution with solid cosolvent 
(RESS-SC) process: formation of griseofulvin nanoparticles. Ind Eng Chem Res 2005; 44: 
7380-7387. 
[46] Thakur R, Gupta RB. Rapid expansion of supercritical solution with solid cosolvent 
(RESS-SC) process: Formation of 2-aminobenzoic acid nanoparticle. J Supercrit Fluid 2006; 
37: 307-315. 
[47] Chiou AHJ, Yeh MK, Chen CY, et al. Micronization of meloxicam using a supercritical fluids 
process. J Supercrit Fluid 2007; 42: 120-128. 
[48] Türk M. Manufacture of submicron drug particles with enhanced dissolution behaviour by 
rapid expansion processes. J Supercrit Fluid 2009; 47: 537-545. 
[49] Weidner E, Knez Z, Novak Z, Inventors. A process and equipment for production and 
fractionation of fine particles from gas saturated solutions, World Patent WO 95/21688. 1994. 
[50] Salmaso S, Elvassore N, Bertucco A, et al. Production of solid lipid submicron particles for 
protein delivery using a novel supercritical gas-assisted melting atomization process. J Pharm 
Sci 2009; 98: 640-650. 
[51] Meterc D, Petermann M, Weidner E. Drying of aqueous green tea extracts using a 
supercritical fluid spray process. J Supercrit Fluid 2008; 45: 253-259. 
[52] Gallagher PM, Coffey MP, Krukonis VJ, et al. Gas antisolvent recrystallization: new process 
to recrystallize compounds insoluble in supercritical fluids. In: Gallagher PM, Coffey MP, 
Krukonis VJ, Eds. Supercritical Fluid Science and Technology. Washington, DC: American 
Chemical Society 1989; pp.334-354. 
[53] De la Fuente Badilla JC, Peters CJ, de Swaan Arons J. Volume expansion in relation to the 
gas-antisolvent process. J Supercrit Fluid 2000; 17: 13-23. 
[54] Palakodaty S, York P, Pritchard J. Supercritical fluid processing of materials from aqueous 
 32 
solutions: the application of SEDS to lactose as a model substance. Pharm Res1998; 15: 
1835-1843. 
[55] He W, Suo Q, Jiang Z H, et al. Precipitation of ephedrine by SEDS process using a specially 
designed prefilming atomizer. J Supercrit Fluid 2004, 31: 101-110. 
[56] He W, Suo Q, Hong H, et al. Production of natural carotene-dispersed polymer microparticles 
by SEDS-PA co-precipitation. J Mater Sci 2007; 42: 3495-3501. 
[57] Chattopadhyay P, Gupta RB. Production of griseofulvin nanoparticles using supercritical CO2 
antisolvent with enhanced mass transfer. Int J Pharm 2001; 228: 19-31. 
[58] Pratsinis S E. Simultaneous nucleation, condensation, and coagulation in aerosol reactors. J 
Colloid Interf Sci 1988; 124: 416-427. 
[59] Kalani A, Christofides P D. Simulation, estimation and control of size distribution in aerosol 
processes with simultaneous reaction, nucleation, condensation and coagulation. Comput 
Chem Eng 2002; 26: 1153-1169. 
[60] Debenedetti PG. Homogeneous nucleation in supercritical fluids. AIChE J 1990; 36: 
1289-1298. 
[61] Friedlander S K, Ed. Smoke, Dust and Haze. New York:̳Oxford University Press, 2000. 
[62] Gupta RB, Shim JJ. Solubility in supercritical carbon dioxide. USA: CRC Press 2006. 
[63] S ޣkerget M, Knez Z, Knez-Hrncޣicޣ M. Solubility of solids in sub-and supercritical fluids: a 
review. J Chem Eng Data 2011; 56: 694-719. 
[64] Li J, Jin J, Zhang Z, et al. Equilibrium solubilities of a p-toluenesulfonamide and 
sulfanilamide mixture in supercritical carbon dioxide with and without ethanol. J Supercrit 
Fluid 2010; 52: 11-17. 
[65] Jiang Y, Liu M, Sun W, et al. Phase Behavior of Poly (lactic acid)/Poly (ethylene glycol)/Poly 
(lactic acid)(PLA-PEG-PLA) in Different Supercritical Systems of CO2+ Dichloromethane 
and CO2+ C2H5OH+ Dichloromethane. J Chem Eng Data 2010; 55: 4844-4848. 
[66] Ashour I, Almehaideb R, Fateen S E, et al. Representation of solid-supercritical fluid phase 
equilibria using cubic equations of state. Fluid Phase Equilibr 2000; 167: 41-61. 
[67] Luo N, Lu Y, Jiang Y. Solubility of paclitaxel in mixtures of dichloromethane and 
supercritical carbon dioxide. Chinese J Chem Eng 2011; 19: 558-564. 
[68] Li S, Varadarajan GS, Hartland S. Solubilities of theobromine and caffeine in supercritical 
carbon dioxide: correlation with density-based models. Fluid Phase Equilibr 1991; 68: 
263-280. 
[69] Sparks DL, Hernandez R, Estévez LA. Evaluation of density-based models for the solubility 
of solids in supercritical carbon dioxide and formulation of a new model. Chem Eng Sci 2008; 
63: 4292-4301. 
[70] Lucien FP, Foster NR. Solubilities of solid mixtures in supercritical carbon dioxide: a review. 
J Supercrit Fluid 2000; 17: 111-134. 
[71] Kirby CF, McHugh MA. Phase behavior of polymers in supercritical fluid solvents. Chem 
Rev 1999; 99: 565-602. 
[72] Elvassore N, Flaibani M, Bertucco A, et al. Thermodynamic analysis of micronization 
processes from gas-saturated solution. Ind Eng Chem Res 2003; 42: 5924-5930. 
[73] Palakodaty S, York P. Phase behavioral effects on particle formation processes using 
supercritical fluids. Pharm Res 1999; 16: 976-985. 
[74] Dixon DJ, Johnston KP, Bodmeier RA. Polymeric materials formed by precipitation with a 
 33 
compressed fluid antisolvent. AIChE J 1993; 39: 127-139. 
[75] Reverchon E, Caputo G, De Marco I. Role of phase behavior and atomization in the 
supercritical antisolvent precipitation. Ind Eng Chem Res 2003; 42: 6406-6414. 
[76] Kayrak D, Akman U, Hortaçsu Ö. Micronization of ibuprofen by RESS. J Supercrit Fluid 
2003; 26: 17-31. 
[77] Hirunsit P, Huang Z, Srinophakun T, et al. Particle formation of ibuprofen-supercritical CO2 
system from rapid expansion of supercritical solutions (RESS): A mathematical model. 
Powder Technol 2005; 154: 83-94. 
[78] Helfgen B, Türk M, Schaber K. Theoretical and experimental investigations of the 
micronization of organic solids by rapid expansion of supercritical solutions. Powder technol 
2000; 110: 22-28. 
[79] Weber M, Russell LM, Debenedetti PG. Mathematical modeling of nucleation and growth of 
particles formed by the rapid expansion of a supercritical solution under subsonic conditions. 
J Supercrit Fluid 2002; 23: 65-80.  
[80] Reverchon E, Pallado P. Hydrodynamic modeling of the RESS process. J Supercrit Fluid 
1996; 9: 216-221. 
[81] Martín A, Cocero MJ. Micronization processes with supercritical fluids: fundamentals and 
mechanisms. Adv Drug Deliver Rev 2008; 60: 339-350. 
[82] Li J, Matos HA, Gomes de Azevedo E. Two-phase homogeneous model for particle 
formation from gas-saturated solution processes. J Supercrit Fluid. 2004; 32: 275-286. 
[83] Li J, Rodrigues M, Paiva A, et al. Modeling of the PGSS process by crystallization and 
atomization. AIChE J 2005; 51: 2343-2357. 
[84] Reverchon E, Torino E, Dowy S, et al. Interactions of phase equilibria, jet fluid dynamics and 
mass transfer during supercritical antisolvent micronization. Chem Eng J 2010; 156: 
446-458.  
[85] 0DUWÕғQ $ &RFHUR 0 - 1XPHULFDO PRGHOLQJ RI MHW K\GURG\QDPLFV PDVV WUDQVIHU DQG
crystallization kinetics in the supercritical antisolvent (SAS) process. J Supercrit Fluid 2004; 
32: 203-219.  
[86] Lengsfeld C S, Delplanque J P, Barocas V H, et al. Mechanism governing microparticle 
morphology during precipitation by a compressed antisolvent: atomization vs nucleation and 
growth. J Phys Chem B 2000; 104: 2725-2735. 
[87] Reverchon E, Adami R, Caputo G, et al. Spherical microparticles production by supercritical 
antisolvent precipitation: interpretation of results. J Supercrit Fluid 2008; 47: 70-84. 
[88] Reverchon E, De Marco I. Mechanisms controlling supercritical antisolvent precipitate 
morphology. Chem Eng J 2011; 169: 358-370.  
[89] Reverchon E, De Marco I, Torino E. Nanoparticles production by supercritical antisolvent 
precipitation: a general interpretation. J Supercrit Fluid 2007; 43: 126-138. 
[90] Reverchon E, De Marco I, Adami R, et al. Expanded micro-particles by supercritical 
antisolvent precipitation: interpretation of results. J Supercrit Fluid 2008; 44: 98-108. 
[91] Rossmann M, Braeuer A, Dowy S, et al. Solute solubility as criterion for the appearance of 
amorphous particle precipitation or crystallization in the supercritical antisolvent (SAS) 
process. J Supercrit Fluid 2012; 66: 350-358. 
[92] Dowy S, Torino E, Luther S K, et al. Imaging the supersaturation in high-pressure systems 
for particle generation. Chem Eng J 2011; 168: 896-902. 
 34 
[93] Werling J O, Debenedetti P G. Numerical modeling of mass transfer in the supercritical 
antisolvent process. J Supercrit Fluid 1999; 16: 167-181. 
[94] Chattopadhyay P, Gupta R B. Protein nanoparticles formation by supercritical antisolvent 
with enhanced mass transfer. AIChE J 2002; 48: 235-244. 
[95] Topp M N. Ultrasonic atomization-a photographic study of the mechanism of disintegration. 
J Aerosol Sci 1973; 4: 17-25. 
[96] Steckel H, Thies J, Müller B W. Micronizing of steroids for pulmonary delivery by 
supercritical carbon dioxide. Int J Pharm 1997; 152: 99-110. 
[97] Todo H, Iida K, Okamoto H, et al. Improvement of insulin absorption from intratracheally 
administrated dry powder prepared by supercritical carbon dioxide process. J Pharm Sci 2003; 
92: 2475-2486. 
[98] Bakhbakhi Y, Charpentier P A, Rohani S. Experimental study of the GAS process for 
producing microparticles of beclomethasone-17, 21-dipropionate suitable for pulmonary 
delivery. Int J Pharm 2006; 309: 71-80. 
[99] Keshavarz A, Karimi-Sabet J, Fattahi A, et al. Preparation and characterization of raloxifene 
nanoparticles using rapid expansion of supercritical solution (RESS). J Supercrit Fluid 2012; 
63: 169-179. 
[100] Varshosaz J, Hassanzadeh F, Mahmoudzadeh M, et al. Preparation of cefuroxime axetil 
nanoparticles by rapid expansion of supercritical fluid technology. Powder Technol 2009; 
189: 97-102. 
[101] Kim M S, Jin S J, Kim J S, et al. Preparation, characterization and in vivo evaluation of 
amorphous atorvastatin calcium nanoparticles using supercritical antisolvent (SAS) process. 
Eur J Pharm Biopharm 2008; 69: 454-465. 
[102] Bolten D, Türk M. Micronisation of carbamazepine through rapid expansion of supercritical 
solution (RESS). J Supercrit Fluid 2012; 62: 32-40. 
[103] Rossmann M, Braeuer A, Leipertz A, et al. Manipulating the size, the morphology and the 
polymorphism of acetaminophen using supercritical antisolvent (SAS) precipitation. J 
Supercrit Fluid 2013; 82: 230-237. 
[104] Jiang Y, Sun W, Wang W. Recrystallization and micronization of 10-hydroxycamptothecin 
by supercritical antisolvent process. Ind Eng Chem Res 2012; 51: 2596-2602.  
[105] Huang Z, Guo Y, Miao H, et al. Solubility of progesterone in supercritical carbon dioxide 
and its micronization through RESS. Powder Technol 2014; 258: 66-77. 
[106] Dalvi S V, Azad M A, Dave R. Precipitation and stabilization of ultrafine particles of 
Fenofibrate in aqueous suspensions by RESOLV. Powder Technol 2013; 236: 75-84. 
[107] Türk M, Bolten D. Formation of submicron poorly water-soluble drugs by rapid expansion 
of supercritical solution (RESS): results for naproxen. J Supercrit Fluid 2010; 55: 778-785. 
[108] Lin P C, Su C S, Tang M, et al. Micronization of tolbutamide using rapid expansion of 
supercritical solution with solid co-solvent (RESS-SC) process. Res Chem Intermediat 2011; 
37: 153-163. 
[109] Chen W, Hu ;+RQJ<HWDO,EXSURIHQQDQRSDUWLFOHVSUHSDUHGE\D3*66-based method. 
Powder Technol 2013; 245: 241-250. 
[110] Esfandiari N, Ghoreishi S M. Synthesis of 5-Fluorouracil nanoparticles via supercritical gas 
antisolvent process. J Supercrit Fluid 2013; 84: 205-210. 
[111] Xu J, Luo K Q. Enhancing the solubility and bioavailability of isoflavone by particle size 
 35 
reduction using a supercritical carbon dioxide-based precipitation process. Chem Eng Res 
Des 2014; In Press. 
[112] Yim J H, Kim W S, Lim J S. Recrystallization of Adefovir Dipivoxil Particles Using the 
Aerosol Solvent Extraction System Process. Ind Eng Chem Res 2014; 53: 1663-1671 
[113] Fraile M, Buratto R, Gómez B, et al. Enhanced delivery of quercetin by encapsulation in 
poloxamers by supercritical antisolvent process. Ind Eng Chem Res 2014; 53: 4318-4327. 
[114] Franceschi E, Kunita M H, Tres M V, et al. Phase behavior and process parameters effects 
on the characteristics of precipitated theophylline using carbon dioxide as antisolvent. J 
Supercrit Fluid 2008; 44: 8-20. 
[115] Chang SC, Lee MJ, Lin H. The influence of phase behavior on the morphology of protein 
Į-chymotrypsin prepared via a supercritical anti-solvent process. J. Supercrit Fluid 2008; 44: 
219-229. 
[116] Baseri H, Lotfollahi M N. Effects of expansion parameters on characteristics of gemfibrozil 
powder produced by rapid expansion of supercritical solution process. Powder Technol 
2014; 253: 744-750. 
[117] Liu G, Wang H, Jiang Y. Recrystallization and Micronization of Camptothecin by the 
Supercritical Antisolvent Process: Influence of Solvents. Ind Eng Chem Res 2013; 52: 
15049-15056.  
[118] Duarte A R C, Costa M S, Simplício A L, et al. Preparation of controlled release 
microspheres using supercritical fluid technology for delivery of anti-inflammatory drugs. 
Int J Pharm 2006; 308: 168-174. 
[119] Lee L Y, Wang C H, Smith K A. Supercritical antisolvent production of biodegradable 
micro-and nanoparticles for controlled delivery of paclitaxel. J Control Release 2008; 125: 
96-106. 
[120] Wang W, Liu G, Wu J, et al. Co-precipitation of 10-hydroxycamptothecin and poly (l-lactic 
acid) by supercritical CO2 anti-solvent process using dichloromethane/ethanol co-solvent. J 
Supercrit Fluid 2013; 74: 137-144. 
[121] Liu G, Wang W, Wang H, et al. Preparation of 10-hydroxycamptothecin proliposomes by the 
supercritical CO2 anti-solvent process. Chem Eng J 2014; 243: 289-296. 
[122] Zu Y, Wang D, Zhao X, et al. A novel preparation method for camptothecin (CPT) loaded 
folic acid conjugated dextran tumor-targeted nanoparticles. Int J Mol Sci 2011; 12: 
4237-4249. 
[123] Zhao X, Jiang R, Zu Y, et al. Process optimization studies of 10-Hydroxycamptothecin 
(HCPT)-loaded folate-conjugated chitosan nanoparticles by SAS-ionic crosslink 
combination using response surface methodology (RSM). Appl Surf Sci 2012; 258: 
2000-2005. 
[124] Vezzù K, Campolmi C, Bertucco A. Production of lipid microparticles magnetically active 
by a supercritical fluid-based process. Int J Chem Eng 2009; 2009: 1-9. 
[125] Chattopadhyay P, Gupta R B. Supercritical CO2 based production of magnetically 
responsive micro-and nanoparticles for drug targeting. Ind Eng Chem Res 2002; 41: 
6049-6058. 
[126] Chen A Z, Li L, Wang S B, et al. Study of Fe3O4-PLLA-PEG-PLLA magnetic microspheres 
based on supercritical CO2: Preparation, physicochemical characterization, and drug 
loading investigation. J Supercrit Fluid 2012; 67: 139-148. 
 36 
[127] Songtipya L, Sane A. Effect of concentration and degree of saturation on co-precipitation of 
catechin and poly (l-lactide) by the RESOLV process. J Supercrit Fluid 2013; 75: 72-80. 
[128] Sane A, Limtrakul J. Co-precipitation of asiatic acid and poly (l-lactide) using rapid 
expansion of subcritical solutions into liquid solvents. J Nanopart Res 2011; 13: 4001-4013. 
[129] Rodrigues M, Peiriço N, Matos H, et al. Microcomposites theophylline/hydrogenated palm 
oil from a PGSS process for controlled drug delivery systems. J Supercrit Fluid 2004; 29: 
175-184. 
[130] GH3D](0DUWtQÈ&RFHUR0-)RUPXODWLRQRIȕ-carotene with soybean lecithin by PGSS 
(Particles from Gas Saturated Solutions)-drying. J Supercrit Fluid 2012; 72: 125-133. 
[131] Montes A, Kin N, Gordillo M D, et al. Polymer-naproxen precipitation by supercritical 
antisolvent (SAS) process. J Supercrit Fluid 2014; 89: 58-67. 
[132] Chen F, Yin G, Liao X, et al. Preparation, characterization and in vitro release properties of 
morphine-loaded PLLA-PEG-PLLA microparticles via solution enhanced dispersion by 
supercritical fluids. J Mater Sci 2013; 24: 1693-1705. 
[133] Zabihi F, Xin N, Li S, et al. Polymeric coating of fluidizing nano-curcumin via anti-solvent 
supercritical method for sustained release. J Supercrit Fluid 2014; 89: 99-105. 
[134] Kim J H, Paxton T E, Tomasko D L. Microencapsulation of naproxen using rapid expansion 
of supercritical solutions[J]. Biotechnol Progr 1996; 12: 650-661. 
[135] Kalani M, Yunus R. Application of supercritical antisolvent method in drug encapsulation: a 
review. Int J Nanomed 2011; 6: 1429-1442. 
 
 37 
Tables 
 
Table 1. The most common administration methods and their advantages and 
disadvantages 
Methods Advantage Disadvantage 
Oral 
administration 
x The preferred route  
x Easy administration 
x Widespread acceptance 
x Low bioavailability 
x Gastrointestinal tract problems 
x Not suitable for drugs targeted 
Injection 
x Rapid onset of action 
x Predictable bioavailability 
x Avoidance gastrointestinal tract 
x Pain involved and patient compliance 
x Dangerous medical waste  
x Disease transmission by needle reuse 
Transdermal 
administration 
x Non-invasive 
x Long release periods  
x Improved patient compliance  
x Significant barrier properties of skin 
x Only a limited number of drugs are 
amenable to administration 
Pulmonary drug 
delivery 
x Large absorption surface area  
x Avoidance of the first pass 
hepatic metabolism 
x High therapeutic effects 
x Drug deposition  
x Deposited particles cleared by the 
mucous toward the throat 
x High demands on the inhalation devices 
 
Table 2. Summary of the SCF PD processes and their mainly operating parameters 
Role of SCF Process Modifications Mainly operating parameters 
Solvent RESS 
RESSOLV 
RESSAS 
RESS-N 
RESS-SC 
PF-RESS 
Extraction T and P 
CO2 flow rate (Fc) 
Solution flow rate (Fs) 
Pre-expansion T and P 
Expansion T 
Nozzle design 
Solute PGSS 
GAMA 
PGSS-drying  
Operating T and P 
Fc and Fs 
Nozzle design 
CO2/solute ratio 
Antisolvent SAS 
GAS 
PCA/ASES 
SEDS 
SEDS-PA 
SAS-EM 
Organic solvent 
Drug concentration (Cd) 
Carrier material concentration (Cc) 
Nozzle design 
Fc and Fs 
T and P 
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Table 3. Examples of SCF micronization processes 
Drug/Method Operating parameters   Results Ref. 
Progesterone/ 
RESS 
Extraction T: 40-60 oC 
Extraction P:120-260 bar 
Dnozzle: 60-ȝP 
PS: ȝPWR-ȝP 
PS decreases with Dnozzle increases, but 
increases with extraction P or T. 
[105] 
Fenofibrate/ 
RESOLV 
Pre-expansion P:100-200 bar 
Dnozzle:127-762 ȝP 
Lnozzle:3-6 cm 
8 different stabilizers 
PS: 0.5-ȝP 
Stabilizers have a great effect on 
particle properties 
[106] 
Naproxen/ 
RESS and 
RESSAS 
Extraction P: 200-300 bar 
Pre-expansion T: 50-90 oC 
Pre-expansion P: 200-300 bar 
PS: 0.56-ȝP (RESS) and ȝP 
(RESSAS)  
RESSAS can effectively minimize 
particle growth 
[107] 
Tolbutamide/ 
RESS and 
RESS-SC 
Extraction T: 35-45 oC 
Extraction P: 150-200 bar 
Pre-expansion T: 120 oC 
Solid co-solvent: Menthol 
PS: 8.5-9.2 ȝP ( RESS) and 2.1- 2.9 
ȝP (RESS-SC) 
The polymorph conversion from form 
I to form II  
[108] 
Ibuprofen/ 
PGSS 
Operating P: 100-250 bar  
Operating T: 50-80 oC 
Fs :1.0 -3.2 ml/min 
Dispersing matrices: 
PEG2000 - PEG6000  
PS: 20-500 nm 
PS decreases with P and molecular 
weight of PEG increases, but increases 
with T or Fs.  
[109] 
5-Fluorouracil /  
GAS 
T: 34-46 oC 
P: 90-150 bar 
Cd: 20-100 mg/mL 
Fs:1.6-2.4 mL/min 
PS:260-600 nm 
PS decreased with decreasing T and Cd 
and with increasing P and Fs 
[110] 
Isoflavone/ 
PCA 
P: 85-120 bar 
Cd: 0.4-4 mg/mL  
Solvent: Acetone, EtOH, 
EtOH+ Acetone 
PS: 10-ȝPWRQPat width 
Reduction PS increased 2 fold water 
solubility and improved 2.6 fold 
plasma concentration after oral 
administration in rat 
[111] 
Adefovir 
Dipivoxil/ 
ASES 
T: 28-50 oC, P: 70-200 bar 
Fs: 0.2-1 mL/min 
Cd: 0.5-2 wt% 
Solvent: ethanol, methanol , 
and isopropyl alcohol (IPA) 
PS decreases with decreased T, Cd and 
Fs, and with increased P. 
The order of solvents was methanol < 
ethanol < IPA 
[112] 
Quercetin/ 
SEDS 
T: 35-45 oC, P: 100-200 bar 
Fs: 1-5 mL/min 
Flow time: 4-20 min 
Cd: 5-10 mg/mL 
Ultrasonic power:100-300 W 
PS: ȝP to 0.12-0.45ȝP 
PS decreases with increasing Fs and 
ultrasonic power, decreasing drug Cd 
and flow time 
[113] 
 
 39 
 
Table 4. Examples of SCF co-precipitation/encapsulation processes 
Drug/ Carrier 
material 
Method Operating parameters   Results Ref. 
Catechin/ 
PLLA 
RESOLV 
Cd: 0.1-0.2 wt%, Cc: 0.2 wt% 
Pre-expansion T: 60-100 oC 
Pre-expansion P:265-325 bar 
Dnozzle: 60-ȝP 
PS: 30-40 nm 
DL: 2.4-7.3% 
EE: 4.7-22.0% 
[127] 
 
Asiatic acid/ 
PLLA 
RESOLV 
Cc: 0.2-0.4 wt% 
Cd/Cc:1:2-1:4 
Pre-expansion T: 70-100 oC 
Pre-expansion P: 330 bar 
PS: 50-54 nm 
DL: 7.6-20.7% 
EE: 37.8-62.2% 
[128] 
 
Theophylline
/ HPO 
PGSS 
Mixing T: 60 oC 
Mixing P: 120-180 bar 
Pre-expansion T: 86 oC 
Fc: 0.18-JPLQí 
PS: 2.5-ȝP 
DL: 0.5 -3.5%  
[129] 
ȕ-carotene/ 
soybean 
lecithin 
PGSS- 
drying 
Cc: 55 -72 g/L 
Operating T: 100-130 oC 
Operating P: 80-100 bar 
Fc / Fs: 21- 37 g/g 
PS: 10-ȝP 
Rehydration PS: 1-ȝP
EE: 29-60% 
[130] 
Quercetin/ 
Pluronic 
F127 
SAS 
Cd: 0.01-0.02 g/mL 
Cd /Cc: 2:1-1:9 
Solvent: acetone 
DL: 35-56% 
The PS and morphology 
are conferred 
[113] 
Naproxen/ 
Eudragit  or 
PLLA 
SAS 
P: 100-200 bar  
T: 40-50 oC 
Content of PEG: 0-5% 
Cd: 5-8 mg/mL  
Cd /Cc: 1:1-1:5 
Naproxen/Eudragit  
PS: 0.56-1.43ȝm  
DL: 3.0-13.2% 
Naproxen/ PLLA 
PS: 0.08-0.31 ȝm  
DL: 4.5-25.6% 
[131] 
Morphine/ 
PLLA-PEG-
PLLA 
SEDS 
P: 80-140 bar, T: 35 oC 
Content of PEG: 0-5% 
Cd: 4-12 mg/mL 
Cd /Cc: 1:5-1:10 
PS: 2.04-5.73ȝP  
DL: 8.3-17.9% 
EE: 51.8-79.0% 
[132] 
Curcumin/ 
PLGA 
SAS-EM 
P: 80-100 bar, T: 23-38 oC 
Fs: 1.0-2.5 mL/min 
Power: 100-180 W 
Solvent: Acetone, Acetone + 
EtOH, EthylAcetate + EtOH 
PS: 40-1680 nm  
DL: 4-38% 
PS and DL can be 
enhanced by increasing 
ultrasound power  
[133] 
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Fig. 1. An overall view of SCF PD for particular drug delivery. 
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Fig. 2. Drug release mechanisms from a polymeric material [25]. 
 
 
  
Fig. 3. Requirements of particle uptake on surface properties [38]. 
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Fig. 4. Influencing mechanism of operating parameters on particle microstructures 
 
 
 
 
A B
 
Fig. 5 P-T-w space diagram of PLA-PEG-PLA in (A) CO2 + DCM system and (B) 
CO2 + DCM + C2H5OH system [65]. 
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Fig. 6. Typical phase diagram for an asymmetric binary mixture consisting of a solid 
(component 2) and CO2 (component 1) at high P [70]. 
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Fig. 7. A simple representative phase diagram of the ternary solid-solvent-scCO2 
systems at constant T and P. 
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Fig. 8. A schematic of the RESS expansion device [77]. 
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Fig. 9. Scattering phenomena related to SAS jet mixing [84]. 
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Fig. 10.The typical SCF PD processes for particular drug delivery 
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Fig. 11. SEM and XRD of unprocessed and SAS processed HCPT [104]. 
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Fig. 12. SEM images of Į-chymotryps in particulate samples prepared from different 
phase regions [115]. 
 
 
 
Fig. 13. Schematic representation of obtained spherical or clavate HCPT-PL under 
different drug loading. 
